Ouachita professor Nathan Reyna invited to National Science Foundation-funded mentor programOuachita Baptist University NewsCurrently, Ouachita has five CURE programs embedded into its curriculum, coordinated primarily by Dr. Reyna and Dr. Ruth Plymale… Continue reading
Ouachita professor Nathan Reyna invited to National Science Foundation-funded mentor programOuachita Baptist University NewsCurrently, Ouachita has five CURE programs embedded into its curriculum, coordinated primarily by Dr. Reyna and Dr. Ruth Plymale… Continue reading
WeAreGreenBay.com |
Healthwatch: Gene Therapy
WeAreGreenBay.com GREEN BAY, Wis. (WFRV) – (CBS News) The Food and Drug Administration approved a treatment that engineers a patient’s own blood cells to fight cancer. It’s the first type of gene therapy to hit the U-S market. It has already been used to treat children … |
The Institute of Cancer Research (blog) |
America approves ‘revolutionary’ CAR T cell immunotherapy — what does this mean for cancer patients?
The Institute of Cancer Research (blog) The treatment, known as CAR T cell therapy, was shown to be effective against blood cancers in clinical trials, and has just been approved by the Food and Drug Administration in the US specifically for children and young adults who have acute … Cancer treatment breakthrough just the beginning for new therapiesThe New Daily |
KSDK |
FDA approves breakthrough gene therapy for childhood leukemia
KSDK The Food and Drug Administration said the approval on Wednesday was historic, the first gene therapy to hit the U.S. market. Made from scratch for every patient, it’s one of a wave of “living drugs” under development to fight additional blood cancers … Pioneering gene therapy approved for leukaemia in the USNew Scientist FDA approval brings first gene therapy to the United StatesFDA.gov First Gene Therapy Treatment Approved in USSmithsonian Los Angeles Times –Novartis –National Cancer Institute –National Cancer Institute all 597 news articles » |
|
Oxford BioMedica could get $100 following CAR–T approval
pharmaphorum UK biotech Oxford BioMedica could earn more than $100 million from Novartis for providing a key component in the recently approved CAR-T cancer cell therapy. The FDA this week approved Novartis’ chimeric antigen receptor T–cell (CAR-T) therapy … |
Phys.Org |
New way to test antibiotics could lead to better drugs
Phys.Org For the new study, Collins wanted to apply synthetic biology—the construction of novel genetic circuits in living cells—to design bacteria that could be used to study antibiotics and infection. Most studies of how antibiotics work are done with … |